NewEdge Advisors’s GSK GSK Stock Holding History

NewEdge Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50M	Buy	953,574 +852,437	+843%	+$45.1M	0.15%	135
2026 Q1	$5.58M	Buy	101,137 +6,583	+7%	+$357K	0.02%	646
2025 Q4	$4.64M	Buy	94,554 +2,477	+3%	+$116K	0.02%	688
2025 Q3	$3.97M	Sell	92,077 -5,335	-5%	-$208K	0.02%	722
2025 Q2	$3.74M	Buy	97,412 +6,749	+7%	+$258K	0.02%	683
2025 Q1	$3.51M	Buy	90,663 +7,148	+9%	+$262K	0.02%	632
2024 Q4	$2.82M	Buy	83,515 +8,262	+11%	+$297K	0.02%	683
2024 Q3	$3.08M	Buy	75,253 +5,205	+7%	+$213K	0.02%	628
2024 Q2	$2.7M	Buy	70,048 +26,793	+62%	+$1.13M	0.02%	642
2024 Q1	$1.85M	Buy	43,255 +1,911	+5%	+$78.8K	0.02%	724
2023 Q4	$1.56M	Buy	41,344 +2,423	+6%	+$87K	0.01%	755
2023 Q3	$1.41M	Buy	38,921 +13,302	+52%	+$472K	0.02%	719
2023 Q2	$913K	Buy	25,619 +2,844	+12%	+$102K	0.01%	909
2023 Q1	$810K	Sell	22,775 -526	-2%	-$18.4K	0.01%	883
2022 Q4	$324K	Buy	+23,301	New	+$776K	0.01%	968
2022 Q3	–	Sell	-17,786	Closed	-$968K	–	1581
2022 Q2	$968K	Sell	17,786 -2,332	-12%	-$129K	0.02%	678
2022 Q1	$1.09M	Buy	20,118 +5,067	+34%	+$275K	0.02%	613
2021 Q4	$830K	Buy	+15,051	New	+$783K	0.01%	832
2020 Q3	–	Sell	-4,494	Closed	-$229K	–	945
2020 Q2	$229K	Sell	4,494 -7,445	-62%	-$382K	0.01%	741
2020 Q1	$565K	Buy	11,939 +6,518	+120%	+$348K	0.03%	426
2019 Q4	$318K	Buy	5,421 +52	+1%	+$2.89K	0.01%	645
2019 Q3	$286K	Buy	5,369 +732	+16%	+$37.7K	0.01%	648
2019 Q2	$232K	Buy	+4,637	New	+$233K	0.01%	583
2018 Q4	–	Sell	-5,649	Closed	-$284K	–	662
2018 Q3	$284K	Buy	+5,649	New	+$287K	0.02%	509
2017 Q3	–	Sell	-1,658	Closed	-$87.5K	–	668
2017 Q2	$87.5K	Buy	+1,658	New	+$88.4K	0.02%	439

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

NewEdge Advisors's GSK Position: Q2 2026 in Review

NewEdge Advisors increased its GSK (GSK) stake by 843% in Q2 2026, buying an estimated $45.1M and bringing the position to 953,574 shares worth $50M. The position accounts for 0.15% of the portfolio, ranked #135.

NewEdge Advisors first reported a position in GSK in Q2 2017 and has held it in 25 quarters since. 1,039 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

NewEdge Advisors held 953,574 shares of GSK worth $50M as of Q2 2026.
NewEdge Advisors bought 852,437 GSK shares in Q2 2026, an estimated $45.1M.
GSK made up 0.15% of NewEdge Advisors's portfolio in Q2 2026, its #135 holding.
NewEdge Advisors first reported a position in GSK in Q2 2017 and has held it in 25 quarters since.
1,039 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.